Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...

Repatha (evolocumab) isn’t known to interact with other medications, supplements, herbs, vitamins, vaccines, or lab tests. There are no known direct interactions between Repatha and alcohol. However, ...

Weeping Peninsula (South Limgrave) - Dungeons, Points of Interest, and Secrets East Liurnia - Dungeons, Points of Interest, and Secrets North Liurnia - Dungeons, Points of Interest, and Secrets West ...

A new gene therapy is giving people born deaf the chance to hear, often within just weeks. In a small but groundbreaking study, researchers delivered a working copy of a key hearing gene directly into ...

April 2 (Reuters) - U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in ...

NEW ORLEANS—Adding the PCSK9 inhibitor evolocumab (Repatha; Amgen) to statin therapy significantly cuts the risk of major cardiovascular events when compared with statins alone in high-risk patients ...

Christos Soteriou was 29 when he needed a quadruple bypass surgery. Four arteries in his heart had become so clogged with plaque that blood could no longer flow through them. Subscribe to read this ...

In the early 1960s, Norwegian physician Kåre Berg, M.D., was trying to identify new blood types when he accidentally discovered a lipoprotein with perplexing properties. Similar to cholesterol, but ...

Investing.com - Cantor Fitzgerald maintained a Neutral rating on Amgen Inc. (NASDAQ:AMGN) stock with a $350.00 price target on Tuesday. The stock currently trades at a P/E ratio of 23.85 with a ...

Please provide your email address to receive an email when new articles are posted on . In patients with diabetes and high LDL but no heart disease, evolocumab reduced major adverse CV events compared ...